Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.

Publication Type
Journal Article
Year of Publication
Salerno-Gon├žalves, Rosangela; Chen, Wilbur H; Mulligan, Mark J; Frey, Sharon E; Stapleton, Jack T; Keitel, Wendy A; Bailey, Jason; Sendra, Eli; Hill, Heather; Johnson, Robert A; Sztein, Marcelo B
Clin Transl Immunology
Date Published
Human; T cells; take; tularaemia; Vaccination

Objectives: , the causative agent of tularaemia, is an exceptionally infectious bacterium, potentially fatal for humans if left untreated and with the potential to be developed as a bioweapon. Both natural infection and live-attenuated vaccine strain (LVS) confer good protection against tularaemia. LVS vaccination is traditionally administered by scarification, and the formation of a cutaneous reaction or take at the vaccination site is recognised as a clinical correlate of protection. Although previous studies have suggested that high antibody titres following vaccination might serve as a useful surrogate marker, the immunological correlates of protection remain unknown.

Methods: We investigated the host T-cell-mediated immune (T-CMI) responses elicited following immunisation with LVS vaccine formulated by the DynPort Vaccine Company (DVC-LVS) or the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS). We compared T-CMI responses prompted by these vaccines and correlated them with take size.

Results: We found that both LVS vaccines elicited similar T-CMI responses. Interestingly, take size associated with the T cells' ability to proliferate, secrete IFN-╬│ and mobilise degranulation, suggesting that these responses play an essential role in tularaemia protection.

Conclusions: These results renew the appreciation for vaccination through the scarification as a prime route of inoculation to target pathogens driving specific T-CMI responses and provide further evidence that T-CMI plays a role in protection from tularaemia.